GlassScriptPhysician profile
Mario A Meallet
NPI 1851510424
$7,097.88
in general payments reported to CMS, 2019-2025
25 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $444 · 2021: $1,498 · 2022: $1,161 · 2023: $714 · 2024: $425 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773 · Entertainment: $22.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.22 |
| Entertainment | $22.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,024.38 | 2019-2022 | |
| Glaukos Corporation | $711.92 | 2019-2025 | Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $707.41 | 2019-2021 | |
| Abbvie INC. | $694.07 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $642.66 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $539.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $498.35 | 2019-2022 | |
| Alcon Vision LLC | $457.64 | 2019-2025 | Argos, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $415.72 | 2022-2025 | Vyzulta, Miebo |
| Carl Zeiss Meditec, INC. | $269.35 | 2019-2021 | |
| Ocular Therapeutix, INC. | $209.39 | 2022-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $168.70 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $148.76 | 2022 | |
| Mallinckrodt Enterprises LLC | $132.46 | 2019 | |
| Rxsight INC | $129.58 | 2021-2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $98.03 | 2021-2025 | Oxervate |
| Akorn Operating Company LLC | $51.34 | 2021 | |
| Thea Pharma INC. | $44.64 | 2022-2023 | Iyuzeh |
| Sight Sciences, INC. | $41.15 | 2021-2023 | Omni Surgical System |
| Akorn, INC. | $39.29 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $23.26 | 2025 | Xdemvy |
| Optos, INC. | $22.43 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Vyera Pharmaceuticals, LLC | $12.65 | 2020 | |
| Biotissue Holdings INC. | $12.49 | 2019 | |
| New World Medical,INC. | $2.39 | 2025 | Via360, Kahook Dual Blade, Streamline |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Meallet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.